Key facts
- Remedy Plan Therapeutics’s last known valuation is $55.0M (Aug 2023).
- It has raised $47.6M; the latest was Later Stage VC ($18.0M) in May 2025.
- Notable investors include Alexandria Venture Investments, Schooner Capital, 20/20 HealthCare Partners, Maryland Tech Council, QB3.
- Status: Privately Held (backing).
- ·The complete investor list — 5 names
- ·Watchlist + deal alerts for Remedy Plan Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for Remedy Plan Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Remedy Plan Therapeutics
Developer of medical drugs designed to halt tumor growth and prevent cancer. The company's drugs disrupt cancer stem cells by transforming the field of NAMPT inhibition with an approach that allows for hyperbolic inhibition, enabling the healthcare industry to address solid tumors, hematologic malignancies, obesity, and autoimmune disorders.
- Sector
- Healthcare
- HQ
- Gaithersburg, MD, United States
- Founded
- 2012
- Employees
- 15
- Website
- remedyplan.com/
- Ownership
- Privately Held (backing)
Remedy Plan Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Remedy Plan Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Remedy Plan Therapeutics in its N-PORT filings yet. We sweep new filings monthly.